MODY
MCID: MTR004
MIFTS: 58

Maturity-Onset Diabetes of the Young (MODY) malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Maturity-Onset Diabetes of the Young

About this section

Aliases & Descriptions for Maturity-Onset Diabetes of the Young:

Name: Maturity-Onset Diabetes of the Young 11 48 24 54 27 13
Mody 11 48 54
Maturity Onset Diabetes Mellitus in Young 68
 
Mason-Type Diabetes 11
Mason Type Diabetes 48

Characteristics:

Orphanet epidemiological data:

54
maturity-onset diabetes of the young:
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-5/10000 (Europe),1-5/10000 (United Kingdom); Age of onset: Adolescent,Adult,Childhood

Classifications:



External Ids:

Disease Ontology11 DOID:0050524
ICD1030 E11.8
Orphanet54 ORPHA552
ICD10 via Orphanet31 E11.9

Summaries for Maturity-Onset Diabetes of the Young

About this section
NIH Rare Diseases:48 Maturity-onset diabetes of the young (mody) is a form of diabetes that is characterized by an early onset diabetes.  mody represents about 2% of all diabetes cases and is commonly misdiagnosed as type 1 or type 2 diabetes mellitus. it is due to a primary defect in pancreatic β-cell function. there are several mody subtypes with distinct genetic causes: mody1, caused by mutations in the hnf4a gene; mody2, caused by mutations in gck gene; mody3 caused by mutations in the hnfa1 (the most common type); mody4 caused by mutations in the pdx1 gene; mody5 caused by mutations in the hnf1b gene; mody6 caused by mutations in the neurod1 gene; mody7 caused by mutations in the klf11 gene; mody8 caused by mutations in the cel gene; mody9 caused by mutations in the pax4 gene; mody10 caused by mutations in the ins gene; mody11 caused by mutations in the blk gene; mody12 caused by mutations in the abcc8 gene; mody13  caused by heterozygous mutation in the kcnj11 gene; and mody14 caused by mutations in the appl1 gene. it is inherited in an autosomal dominant pattern. treatment depends on the subtype and may include sulfonylureas, insulin or diet and exercise. last updated: 4/20/2016

MalaCards based summary: Maturity-Onset Diabetes of the Young, also known as MODY, is related to maturity-onset diabetes of the young, type 13 and maturity-onset diabetes of the young 6. An important gene associated with Maturity-Onset Diabetes of the Young is GCK (Glucokinase), and among its related pathways are Dichloroethylene metabolism and Cori Cycle. Affiliated tissues include testes, kidney and pancreas, and related mouse phenotypes are Decreased free cholesterol and Decreased viability.

Disease Ontology:11 A genetic disease that has material basis in mutations in the MODY genes disrupting insulin production.

Wikipedia:71 \"Maturity onset diabetes of the young\" (MODY) refers to any of several hereditary forms of diabetes... more...

Related Diseases for Maturity-Onset Diabetes of the Young

About this section

Diseases in the Maturity-Onset Diabetes of the Young family:

Maturity-Onset Diabetes of the Young, Type Vii Maturity-Onset Diabetes of the Young 6
Maturity-Onset Diabetes of the Young, Type 14 Maturity-Onset Diabetes of the Young, Type Ix
Maturity-Onset Diabetes of the Young, Type 11 Maturity-Onset Diabetes of the Young, Type Viii
Maturity-Onset Diabetes of the Young, Type 10 Maturity-Onset Diabetes of the Young, Type 13

Diseases related to Maturity-Onset Diabetes of the Young via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 61)
idRelated DiseaseScoreTop Affiliating Genes
1maturity-onset diabetes of the young, type 1334.2ABCC8, GCK, HNF4A, INS, KCNJ11
2maturity-onset diabetes of the young 633.9ABCC8, GCK, GCKR, HNF1A, HNF1B, HNF4A
3maturity-onset diabetes of the young, type viii12.7
4maturity-onset diabetes of the young, type vii12.7
5maturity-onset diabetes of the young, type ix12.7
6maturity-onset diabetes of the young, type 1112.7
7maturity-onset diabetes of the young, type 1012.7
8maturity-onset diabetes of the young, type 1412.6
9fanconi renotubular syndrome 4, with maturity-onset diabetes of the young12.6
10renal cysts and diabetes syndrome12.3
11mody, type i12.1
12mody, type iii12.1
13mody, type iv12.1
14mody, type ii12.1
15diabetes mellitus, transient neonatal, 111.0
16fanconi renotubular syndrome 111.0
17hemochromatosis, type 410.3HNF1A, NEUROD1
18biliary cirrhosis, primary, 510.3HNF1B, HNF4A
19antidepressant type abuse10.3GCK, HNF1A, INS, KCNJ11
20pleuropulmonary blastoma10.3HNF1A, INS
21pancreatitis10.3
22progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 610.2NEUROD1, NEUROG3
23hypoglycemia10.2
24nosophobia10.2ABCC8, GCK, KCNJ11
25diaphanospondylodysostosis10.2ABCC8, GCK
26hepatitis10.2
27labyrinthine unilateral reactive loss10.2ABCC8, GCK, INS, KCNJ11
28alopecia-mental retardation syndrome 210.2ABCC8, INS, SLC2A2
29paroxysmal nonkinesigenic dyskinesia 210.2INS, NEUROD1
30autoimmune disease 110.2ABCC8, INS, KCNJ11
31deafness, autosomal recessive 6610.2ABCC8, INS, KCNJ11
32neurogenic arthropathy10.2ABCC8, GCK, INS, KCNJ11
33non-syndromic intellectual disability10.1ABCC8, GCK, INS, KCNJ11, PDX1
34diabetic cataract10.1ABCC8, GCK, HNF4A, INS, KCNJ11
35chondroma10.1ABCC8, INS, KCNJ11
36exostosis10.1ABCC8, GCK, HNF4A, INS, KCNJ11
37ischemic heart disease10.1ABCC8, GCK, INS, PDX1, SLC2A2
38diabetes mellitus, insulin-dependent, 2010.1GCK, HNF1A, HNF1B, HNF4A, INS, KCNJ11
39peroneal neuropathy10.1ABCC8, GCK, INS, KCNJ11, SLC2A2
40noonan syndrome 310.1ABCC8, KCNJ11
41body dysmorphic disorder10.1ABCC8, GCK, INS, KCNJ11, SLC2A2
42focal segmental glomerulosclerosis 810.1ABCC8, GCK, INS, KCNJ11, NEUROG3, PDX1
43brain stem glioma10.1ABCC8, GCK, HNF1A, INS, KCNJ11, PDX1
44distal muscular dystrophy10.0ABCC8, GCK, HNF1B, INS, KCNJ11, NEUROD1
45hyperinsulinemic hypoglycemia10.0
46duodenitis10.0
47mosaic trisomy 1310.0ABCC8, CEL, GCK, HNF1A, HNF1B, HNF4A
48obesity9.9
49hyperglycemia9.9
50colorectal cancer9.8

Graphical network of the top 20 diseases related to Maturity-Onset Diabetes of the Young:



Diseases related to maturity-onset diabetes of the young

Symptoms & Phenotypes for Maturity-Onset Diabetes of the Young

About this section

GenomeRNAi Phenotypes related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00340-A-211.1GCKR, HNF1A, HNF4A
2GR00381-A-110.8APPL1, BLK, GCK, GCKR, PKLR
3GR00343-S9.5BLK, CEL, GCK, HNF1A, HNF4A, KCNJ11

MGI Mouse Phenotypes related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538110.6CEL, FOXA2, HNF1A, INS, NEUROD1, NEUROG3
2MP:000537510.6APPL1, CEL, FOXA2, HNF1A, INS, KCNJ11
3MP:000536910.6APPL1, HNF1A, HNF1B, INS, KCNJ11, PDX1
4MP:000301210.6ABCC8, APPL1, HNF1A, INS, KCNJ11, NEUROG3
5MP:000536710.6GCK, HNF1A, HNF1B, INS, NEUROD1, NEUROG3
6MP:000537010.4CEL, FOXA2, GCK, HNF1A, HNF1B, HNF4A
7MP:000287310.2BLK, FOXA2, HNF4A, INS, KLF11, NEUROG3
8MP:00053799.8ABCC8, BLK, FOXA2, GCK, HNF1A, HNF1B
9MP:00053789.7APPL1, CEL, FOXA2, GCK, HNF1A, HNF1B
10MP:00107689.7APPL1, FOXA2, GCK, HNF1A, HNF1B, HNF4A
11MP:00053769.3ABCC8, APPL1, CEL, FOXA2, GCK, GCKR

Drugs & Therapeutics for Maturity-Onset Diabetes of the Young

About this section

Drugs for Maturity-Onset Diabetes of the Young (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 237)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MetforminapprovedPhase 4, Phase 3, Phase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
2
CilostazolapprovedPhase 410673963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
3MoxonidineapprovedPhase 41375438-57-24810
4
Insulin GlargineapprovedPhase 4528160337-95-1
Synonyms:
 
Insulin Glargine (rDNA origin)
Insulin glargine recombinant
5
PitavastatinapprovedPhase 466147511-69-1, 147526-32-76366718, 5282452
Synonyms:
( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
111GE002
147511-69-1
147526-32-7
2C25H23FNO4.Ca
AC1NR03G
AC1NR03J
AKOS005145916
Alipza
Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt
C13334
CCRIS 8652
CID5282451
CID5282452
D01862
Itavastatin
Itavastatin calcium
KS-1220
LS-190698
 
LS-74594
LS-74595
Livalo
Livalo (TN)
Livalo, Pitavastatin calcium
Livazo
MolPort-006-822-984
NK 104
NK-104
NKS-104
Nisvastatin
P 872441
P-872441
Pitavastatia
Pitavastatin
Pitavastatin [INN]
Pitavastatin calcium
Pitavastatin calcium (JAN)
Pitavastatin hemicalcium
Pitavastatine
Pitavastatinum
S1759_Selleck
ZINC01534965
calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
6
GlimepirideapprovedPhase 4, Phase 2, Phase 323493479-97-13476
Synonyms:
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
64598P
93479-97-1
AB00513874
AC-476
AC1L1G0T
Amarel
Amaryl
Amaryl (TN)
Amaryl, Glista OD, Glimepiride
Avaglim
BPBio1_000751
BRD-K34776109-001-03-4
BRD-K42693031-001-01-8
BRN 5365754
BSPBio_000681
Bio-0049
C07669
C24H34N4O5S
CAS-93479-97-1
CCRIS 7083
CHEBI:5383
CHEMBL1481
CID3476
CPD000466368
D00593
DB00222
Endial
G2295_SIGMA
Glimepirid
Glimepirida
Glimepirida [Spanish]
Glimepiride (JAN/USP/INN)
Glimepiride [USAN:BAN:INN]
Glimepiridum
Glimepiridum [Latin]
 
Glimepride
Glimer
Glimépiride
Glymepirid
HMS1570C03
HMS2052L03
HMS2090K18
HOE 490
Hoe-490
I06-0029
I06-2285
LS-136752
MLS000759495
MLS001076674
MLS001401419
MolPort-003-847-587
MolPort-003-987-461
MolPort-005-941-721
NCGC00016960-01
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
Novo-glimepiride
Oprea1_382896
PMS-glimepiride
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
Ratio-glimepiride
Roname
S1344_Selleck
SAM001246710
SMR000466368
SPBio_002602
Sandoz glimepiride
Solosa
TL8005924
UNII-6KY687524K
ZINC00537791
glimepiride
7
Exenatideapproved, investigationalPhase 4, Phase 3, Phase 2296141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
8
ZincapprovedPhase 4, Phase 3, Phase 122967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
9
MentholapprovedPhase 4, Phase 326062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
10
EthanolapprovedPhase 4213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
11
Insulin AspartapprovedPhase 4442116094-23-616132418
Synonyms:
(AspB28)-human insulin
1024611-56-0
116094-23-6
139532-40-4
28(sup B)-L-Aspartic acid-insulin (human)
877034-90-7
AspB28-insulin (human)
Aspart
Aspart Insulin
Aspart insulin
B28-Asp-insulin
B28-Aspart-Insulin
INA-X 14
 
INA-X14
Insulin X14
Insulin aspart
Insulin aspart [USAN]
Insulin aspart protamine recombinant
Insulin aspart recombinant
Insulin, Asp(B28)
LS-185932
NovoLog
NovoMix 30
NovoRapid
NovoRapid 30 Mix
Novolog mix 70/30
UNII-D933668QVX
12
Insulin DetemirapprovedPhase 4195169148-63-45311023
Synonyms:
Detemir
 
Insulin detemir recombinant
Insulin,detemir,human
13
SofosbuvirapprovedPhase 42591190307-88-045375808
Synonyms:
 
S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate
SOVALDI
14
MirabegronapprovedPhase 495223673-61-8
Synonyms:
 
Myrbetriq
15
RibavirinapprovedPhase 4100336791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
16
LedipasvirapprovedPhase 41071256388-51-867505836
Synonyms:
 
methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate
17
Ritonavirapproved, investigationalPhase 4883155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
18
Aspirinapproved, vet_approvedPhase 4115250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide acetylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
 
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
acide 2-(acétyloxy)benzoïque
acide acétylsalicylique
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
ácido acetilsalicílico
19Liver ExtractsPhase 4, Phase 34067
20Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 113168
21Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 113180
22IncretinsPhase 4, Phase 2, Phase 3, Phase 11579
23Sitagliptin PhosphatePhase 4, Phase 3423
24Bronchodilator AgentsPhase 4, Phase 22965
25Fibrinolytic AgentsPhase 42388
26Neuroprotective AgentsPhase 41716
27Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 123689
28Autonomic AgentsPhase 4, Phase 210150
29Anti-Asthmatic AgentsPhase 4, Phase 2, Phase 13488
30insulinPhase 4, Phase 3, Phase 2, Phase 14646
31Insulin, Globin ZincPhase 4, Phase 3, Phase 2, Phase 14645
32Antihypertensive AgentsPhase 4, Phase 34207
33Phosphodiesterase 3 InhibitorsPhase 4133
34Phosphodiesterase InhibitorsPhase 4, Phase 21289
35HormonesPhase 4, Phase 2, Phase 3, Phase 114415
36Hypoglycemic AgentsPhase 4, Phase 2, Phase 3, Phase 15896
37Respiratory System AgentsPhase 4, Phase 2, Phase 14997
38Vasodilator AgentsPhase 4, Phase 23543
39Protective AgentsPhase 4, Phase 17443
40Platelet Aggregation InhibitorsPhase 42516
41Anti-Infective AgentsPhase 422062
42
protease inhibitorsPhase 4, Phase 35471
Synonyms:
 
protease inhibitors
43HIV Protease InhibitorsPhase 4, Phase 35470
44Anti-Inflammatory Agents, Non-SteroidalPhase 44443
45Antirheumatic AgentsPhase 4, Phase 2, Phase 110956
46Analgesics, Non-NarcoticPhase 46501
47AnalgesicsPhase 4, Phase 111733
48Pharmaceutical SolutionsPhase 4, Phase 3, Phase 28192
49Antiviral AgentsPhase 49967
50Anti-Inflammatory AgentsPhase 410729

Interventional clinical trials:

(show top 50)    (show all 167)
idNameStatusNCT IDPhase
1Thyroid Study Type 2 Diabetes Mellitus (T2DM)Unknown statusNCT01379170Phase 4
2Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With ObesityUnknown statusNCT01180231Phase 4
3Effects of Cilostazol on Plasma Adipocytokine and Arterial StiffnessUnknown statusNCT00573950Phase 4
4Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study PopulationCompletedNCT00964184Phase 4
5Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With HypercholesterolemiaCompletedNCT00889226Phase 4
6Management of Type-2 Diabetic Patients Treated With Insulin During the RamadanCompletedNCT01354925Phase 4
7Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)CompletedNCT00708578Phase 4
8Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)CompletedNCT00562172Phase 4
9Exenatide and Brown Adipose TissueRecruitingNCT03002675Phase 4
10Mirabegron and Brown Adipose TissueRecruitingNCT03012113Phase 4
11A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic NephropathyRecruitingNCT01191983Phase 4
12Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 DiabetesRecruitingNCT02235298Phase 4
13Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)RecruitingNCT02500147Phase 4
14Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)RecruitingNCT02512523Phase 4
15Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular DysfunctionRecruitingNCT02590822Phase 4
16Study of Oral Treatments for Hepatitis CRecruitingNCT02786537Phase 4
17Metformin in Longevity StudyActive, not recruitingNCT02432287Phase 4
18Autoimmune Diabetes Accelerator Prevention TrialEnrolling by invitationNCT02881528Phase 4
19Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM PatientsNot yet recruitingNCT02933788Phase 4
20The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young AdultsWithdrawnNCT00845559Phase 4
21Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerUnknown statusNCT00551733Phase 3
22The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)CompletedNCT01610934Phase 2, Phase 3
23Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in OsteoporosisCompletedNCT00500409Phase 3
24Extension Study for 2993-112CompletedNCT01789957Phase 3
25Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a SulfonylureaCompletedNCT00039026Phase 3
26Type 2 Diabetes Primary Prevention for At Risk GirlsCompletedNCT00063674Phase 2, Phase 3
27Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)CompletedNCT00437554Phase 3
28Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP ChannelsCompletedNCT02375828Phase 3
29Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)RecruitingNCT02043054Phase 3
30Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular HypertensionRecruitingNCT02250651Phase 3
31An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionRecruitingNCT01560637Phase 3
32Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial HypertensionRecruitingNCT01560624Phase 3
33Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentRecruitingNCT02548351Phase 3
34Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar DisorderRecruitingNCT02519543Phase 3
35Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .Active, not recruitingNCT02387749Phase 2, Phase 3
36Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes MellitusNot yet recruitingNCT02838147Phase 3
37Efficacy of Foot Orthotics in Veterans With Chronic Lower Back PainTerminatedNCT01865539Phase 2, Phase 3
38A Study to Determine the Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Dark CirclesUnknown statusNCT01644448Phase 1, Phase 2
39The Effects of California Strawberries on Parameters of Cardiovascular HealthUnknown statusNCT01705093Phase 2
40Clinical Trial of YH14618 in Patients With Degenerative Disc DiseaseCompletedNCT02320019Phase 2
41Open-label Study of STA-9090 for Patients With Metastatic Breast CancerCompletedNCT01273896Phase 2
42RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARDCompletedNCT02128113Phase 2
43A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With DyslipidemiaCompletedNCT01539616Phase 2
44Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy StudyCompletedNCT01007266Phase 2
45Stem Cell Educator Therapy in Type 2 DiabetesCompletedNCT01415726Phase 1, Phase 2
46Translating the DPP Into the CommunityCompletedNCT00302042Phase 2
47Mobile Device Outcomes-based Rehabilitation ProgramRecruitingNCT02891707Phase 1, Phase 2
48Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)RecruitingNCT02766465Phase 2
49Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMIActive, not recruitingNCT02794402Phase 2
50Theophylline Treatment for PseudohypoparathyroidismNot yet recruitingNCT03029429Phase 2

Search NIH Clinical Center for Maturity-Onset Diabetes of the Young

Genetic Tests for Maturity-Onset Diabetes of the Young

About this section

Genetic tests related to Maturity-Onset Diabetes of the Young:

id Genetic test Affiliating Genes
1 Maturity Onset Diabetes Mellitus in Young27
2 Maturity-Onset Diabetes of the Young27 24

Anatomical Context for Maturity-Onset Diabetes of the Young

About this section

MalaCards organs/tissues related to Maturity-Onset Diabetes of the Young:

36
Testes, Kidney, Pancreas, Liver, Uterus, Thyroid

Publications for Maturity-Onset Diabetes of the Young

About this section

Articles related to Maturity-Onset Diabetes of the Young:

(show top 50)    (show all 308)
idTitleAuthorsYear
1
An analysis of the sequence of the BAD gene among patients with maturity-onset diabetes of the young (MODY). (27935851)
2017
2
Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data. (28012402)
2017
3
Maturity onset diabetes of the young 5 accompanied by duodenal cysts. (26676964)
2016
4
A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. (27852188)
2016
5
ABCC8-Related Maturity-Onset Diabetes of the Young (MODY12): Clinical Features and Treatment Perspective. (27538677)
2016
6
Studies of genetic variability of the hepatocyte nuclear factor-1I+ gene in an Indian maturity-onset diabetes of the young family. (27148439)
2016
7
A Single Nucleotide Variant in HNF-1I^ is Associated with Maturity-Onset Diabetes of the Young in a Large Chinese Family. (27114981)
2016
8
Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment. (27130141)
2016
9
Genetic Confirmation Rate in Clinically Suspected Maturity-Onset Diabetes of the Young. (27634015)
2016
10
Maturity onset diabetes of the young: Seek and you will find. (27323672)
2016
11
GCK gene mutations are a common cause of childhood-onset MODY (maturity-onset diabetes of the young) in Turkey. (27256595)
2016
12
Divergent phenotypes in siblings with identical novel mutations in the HNF-1I+ gene leading to maturity onset diabetes of the young type 3. (27142837)
2016
13
Searching for Maturity-Onset Diabetes of the Young (MODY): When and What for? (27103109)
2016
14
A three-step programmed method for the identification of causative gene mutations of maturity onset diabetes of the young (MODY). (27185633)
2016
15
Maturity-Onset Diabetes of the Young: A Genetic Form of Diabetes in Children. (27955956)
2016
16
Urinary C-Peptide/Creatinine Ratio Can Distinguish Maturity-Onset Diabetes of the Young from Type 1 Diabetes in Children and Adolescents: A Single-Center Experience. (25792383)
2015
17
Hepatocellular Carcinoma Arising in an HNF-1I+-Mutated Adenoma in a 23-Year-Old Woman with Maturity-Onset Diabetes of the Young: A Case Report. (26676820)
2015
18
Maturity-Onset Diabetes of the Young: What Do Clinicians Need to Know? (26706916)
2015
19
Molecular diagnosis of maturity-onset diabetes of the young (MODY) in Turkish children by using targeted next-generation sequencing. (26226118)
2015
20
Hepatocyte nuclear factor-I+ genetic mutation in a Chinese pedigree with maturity-onset diabetes of the young (MODY3). (26436572)
2015
21
Molecular and phenotypic characteristics of maturity-onset diabetes of the young compared with early onset type 2 diabetes in China. (25588466)
2015
22
The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young. (25935773)
2015
23
Hepatocyte nuclear factor 1I+-inactivated hepatocellular adenomatosis in a patient with maturity-onset diabetes of the young type 3: case report and literature review. (26346360)
2015
24
A genetic diagnosis of maturity-onset diabetes of the young (MODY): experiences of patients and family members. (25763774)
2015
25
Characteristics of maturity onset diabetes of the young in a large diabetes center. (26059258)
2015
26
Maturity-onset diabetes of the young (MODY): an update. (25581748)
2015
27
Frameshift mutations in the insulin gene leading to prolonged molecule of insulin in two families with Maturity-Onset Diabetes of the Young. (25721872)
2015
28
Establishment of maturity-onset diabetes of the young-induced pluripotent stem cells from a Japanese patient. (26417411)
2015
29
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. (25953829)
2015
30
A novel nonsense mutation of the HNF1I+ in maturity-onset diabetes of the young type 3 in Asian population. (26050565)
2015
31
The complexity of elucidating whether novel mutations in the hepatocyte nuclear factor one alpha gene are responsible for maturity onset diabetes of the young in ethnic minorities. (26393317)
2015
32
A novel heterozygous mutation in the glucokinase gene is responsible for an early-onset mild form of maturity-onset diabetes of the young, type 2. (25921421)
2015
33
Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G>A mutation causing maturity-onset diabetes of the young, type 9. (25951767)
2015
34
Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential. (26324089)
2015
35
MODY2" (maturity onset diabetes of the young type 2). (25622392)
2014
36
Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing. (25041077)
2014
37
Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. (25332292)
2014
38
Maturity onset diabetes of the young (MODY)-History, first case reports and recent advances. (25281821)
2014
39
Identification and Functional Characterization of P159L Mutation in HNF1B in a Family with Maturity-Onset Diabetes of the Young 5 (MODY5). (25705165)
2014
40
Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid. (24062244)
2014
41
Genetic causes of maturity onset diabetes of the young may be less prevalent in American pregnant women recently diagnosed with diabetes mellitus than in previously studied European populations. (25012807)
2014
42
Current and Best Practices of Genetic Testing for Maturity Onset Diabetes of the Young: Views of Professional Experts. (25341961)
2014
43
Clinical utility gene card for: Maturity-onset diabetes of the young. (24518839)
2014
44
A family with a novel termination mutation in hepatic nuclear factor 1I+ in maturity-onset diabetes of the young type 3 which is unresponsive to sulphonylurea therapy. (24642958)
2014
45
Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients. (24804978)
2014
46
Structural and functional study of the GlnB22-insulin mutant responsible for maturity-onset diabetes of the young. (25423173)
2014
47
Comparability of high-sensitivity CRP methods to detect maturity-onset diabetes of the young due to HNF1A mutations. (24974685)
2014
48
Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Disease Protein Biomarkers in Secretin-Stimulated Duodenal Juice. (25369532)
2014
49
Low serum level of high-sensitivity C-reactive protein in a Japanese patient with maturity-onset diabetes of the young type 3 (MODY3). (25411618)
2014
50
Maturity-onset diabetes of the young type 5 in a family with diabetes and mild kidney disease diagnosed by whole exome sequencing. (25367728)
2014

Variations for Maturity-Onset Diabetes of the Young

About this section

Expression for genes affiliated with Maturity-Onset Diabetes of the Young

About this section
Search GEO for disease gene expression data for Maturity-Onset Diabetes of the Young.

Pathways for genes affiliated with Maturity-Onset Diabetes of the Young

About this section

Pathways related to Maturity-Onset Diabetes of the Young according to KEGG:

34
id Name KEGG Source Accession
1Maturity onset diabetes of the younghsa04950

Pathways related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

(show all 13)
idSuper pathwaysScoreTop Affiliating Genes
110.3HNF1A, HNF4A
210.3INS, SLC2A2
3
Show member pathways
10.1GCK, GCKR, SLC2A2
410.1FOXA2, NEUROD1, NKX2-2
5
Show member pathways
9.9ABCC8, INS, KCNJ11, PKLR, SLC2A2
6
Show member pathways
9.9ABCC8, GCK, INS, KCNJ11, PDX1, SLC2A2
79.8FOXA2, GCKR, HNF1A, HNF4A, INS, NEUROD1
8
Show member pathways
9.6FOXA2, GCK, HNF1A, HNF1B, HNF4A, INS
99.5FOXA2, HNF1B, INS, NEUROD1, NEUROG3, NKX2-2
109.4ABCC8, FOXA2, GCK, HNF1A, HNF4A, INS
11
Show member pathways
9.3ABCC8, GCK, HNF1A, HNF1B, HNF4A, INS
12
Show member pathways
9.1FOXA2, GCK, HNF1A, HNF1B, HNF4A, INS
13
Show member pathways
9.1FOXA2, GCK, HNF1A, HNF1B, HNF4A, INS

GO Terms for genes affiliated with Maturity-Onset Diabetes of the Young

About this section

Cellular components related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ATP-sensitive potassium channel complexGO:000828211.0ABCC8, KCNJ11
2nucleoplasmGO:00056549.4FOXA2, GCK, GCKR, HNF1B, HNF4A, KLF11

Biological processes related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

(show all 35)
idNameGO IDScoreTop Affiliating Genes
1detection of glucoseGO:005159411.1GCK, PDX1
2negative regulation of gluconeogenesisGO:004572111.1GCK, INS
3positive regulation of glycogen biosynthetic processGO:004572511.1GCK, INS
4negative regulation of type B pancreatic cell apoptotic processGO:200067511.1NEUROD1, PDX1
5nitric oxide mediated signal transductionGO:000726311.1NEUROD1, PDX1
6positive regulation of transcription initiation from RNA polymerase II promoterGO:006026111.1HNF1A, HNF1B
7regulation of pronephros sizeGO:003556511.1HNF1A, HNF1B
8signal transduction involved in regulation of gene expressionGO:002301911.1HNF4A, NEUROD1
9pancreatic A cell fate commitmentGO:000332611.1NEUROD1, NKX2-2
10pancreatic PP cell fate commitmentGO:000332911.1NEUROD1, NKX2-2
11negative regulation of glucokinase activityGO:003313211.0FOXA2, GCKR
12positive regulation of insulin secretionGO:003202411.0BLK, GCK, PDX1
13response to ATPGO:003319811.0KCNJ11, PKLR
14liver developmentGO:000188911.0HNF1A, HNF1B, PDX1
15glucose transportGO:001575811.0GCK, INS, SLC2A2
16cellular glucose homeostasisGO:000167811.0ABCC8, GCK, GCKR
17hindbrain developmentGO:003090210.9HNF1B, NEUROD1, NEUROG3
18glucose metabolic processGO:000600610.9GCK, INS, KCNJ11, PDX1
19positive regulation of neuron differentiationGO:004566610.9NEUROD1, NEUROG3, NKX2-2
20positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.9NEUROD1, NEUROG3, NKX2-2
21insulin secretionGO:003007310.9HNF1A, HNF1B, NEUROD1, PDX1
22glucose homeostasisGO:004259310.8GCK, HNF1A, HNF4A, INS, NEUROD1, PDX1
23positive regulation of cell differentiationGO:004559710.7INS, NEUROD1, NEUROG3, NKX2-2, PAX4
24carbohydrate metabolic processGO:000597510.7GCK, GCKR, INS, PKLR, SLC2A2
25positive regulation of transcription, DNA-templatedGO:004589310.7FOXA2, HNF1A, HNF1B, HNF4A, NEUROD1, PDX1
26transcription from RNA polymerase II promoterGO:000636610.6HNF1A, HNF4A, KLF11, NEUROD1, NEUROG3, PDX1
27cell differentiationGO:003015410.6BLK, NEUROD1, NEUROG3, NKX2-2, PAX4, PDX1
28response to drugGO:004249310.6ABCC8, HNF1B, KCNJ11, NEUROD1, PAX4, PDX1
29regulation of insulin secretionGO:005079610.6ABCC8, GCK, HNF1A, HNF4A, KCNJ11, NEUROD1
30endocrine pancreas developmentGO:003101810.5FOXA2, HNF1A, NEUROD1, NEUROG3, NKX2-2, PAX4
31response to glucoseGO:000974910.5HNF1A, HNF1B, HNF4A, NEUROD1, NKX2-2, PDX1
32positive regulation of transcription from RNA polymerase II promoterGO:004594410.4FOXA2, HNF1A, HNF1B, HNF4A, NEUROD1, NEUROG3
33transdifferentiationGO:006029010.3NEUROG3, PDX1
34regulation of transcription, DNA-templatedGO:000635510.1FOXA2, HNF1A, HNF1B, HNF4A, INS, KLF11
35transcription, DNA-templatedGO:00063519.6FOXA2, HNF1A, HNF1B, HNF4A, KLF11, NEUROD1

Molecular functions related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1ATP-activated inward rectifier potassium channel activityGO:001527211.1ABCC8, KCNJ11
2core promoter proximal region DNA bindingGO:000115911.0HNF1B, NKX2-2
3potassium ion bindingGO:003095511.0KCNJ11, PKLR
4transcription factor activity, RNA polymerase II distal enhancer sequence-specific bindingGO:000370510.9HNF1B, HNF4A, PDX1
5double-stranded DNA bindingGO:000369010.8HNF1A, NEUROD1, NEUROG3, PAX4
6RNA polymerase II core promoter proximal region sequence-specific DNA bindingGO:000097810.7FOXA2, HNF1A, NEUROD1, NEUROG3, PDX1
7transcription factor bindingGO:000813410.6FOXA2, HNF1A, NEUROD1, NKX2-2, PDX1
8transcription regulatory region DNA bindingGO:004421210.6FOXA2, HNF1A, HNF1B, HNF4A, KLF11
9sequence-specific DNA bindingGO:004356510.4FOXA2, HNF1A, HNF1B, HNF4A, NEUROD1, NKX2-2
10transcription factor activity, sequence-specific DNA bindingGO:000370010.2FOXA2, HNF1A, HNF1B, HNF4A, KLF11, NEUROD1
11DNA bindingGO:000367710.2FOXA2, HNF1A, HNF1B, HNF4A, KLF11, NEUROD1
12transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingGO:000107710.1HNF1A, HNF4A, NEUROD1, NEUROG3

Sources for Maturity-Onset Diabetes of the Young

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet